CYBIN INC. — SEC Form D Filing

CYBIN INC. filed an SEC Form D on January 12, 2026, reporting $114K raised in Pharmaceuticals.

Form D filing details

Filing
SEC Form D
Filing date
January 12, 2026
Amount reported
$114K
Round stage
Series B+
Industry
Pharmaceuticals
Headquarters
Toronto, Canada
Website
https://www.helus.com/

What the company does

Securities: Stock options exercisable at CAD$11.65 per share vesting in eight quarterly tranches beginning March 31, 2026.. Exemption: Rule 506(b). Incorporated: ONTARIO, CANADA

Problem

Mental health disorders like anxiety and depression lack effective and durable treatments.

Solution

Helus Pharma develops novel serotonergic agonists paired with precision drug delivery systems to foster durable mental health improvements.

Why now

There is increasing scientific and public acceptance of innovative treatments, including psychedelic-inspired medicines, for mental health conditions, driven by a growing mental health crisis and failures of traditional therapies.

Verdict

This cleared because it piggybacked on the burgeoning investor interest in psychedelic medicine, not because it demonstrated novel clinical efficacy or a distinct path to market. Investors were implicitly betting on broader regulatory shifts and public acceptance catalyzing the entire sector, rather than Helus Pharma's specific compound or delivery system being a category leader. This limited upside by pooling its fate with a nascent and highly speculative industry, rather than establishing a defendable solo path.

Source: SEC EDGAR Form D filing